Prognostic features and role of liver transplantation in severe corticosteroid‐treated autoimmune chronic active hepatitis

Hepatology

Volumn 15, Issue 2, 1992, Pages 215-221

  Sanchez‐Urdazpal, Luis ^a   Czaja, Albert J ^a   van Hoek, Bart ^a   Krom, Ruud A F ^a   Wiesner, Russell H ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; PREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNE DISEASES; CHRONIC DISEASE; COMPARATIVE STUDY; FEMALE; HEPATITIS; HUMAN; LIVER TRANSPLANTATION; MALE; MUSCLE, SMOOTH; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0026571063     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840150208     Document Type: Article

References (40)

1. Autoimmune features as determinants of prognosis in steroid‐treated chronic active hepatitis of uncertain etiology
2. Natural history, clinical features, and treatment of autoimmune hepatitis
3. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg‐negative chronic active hepatitis
4. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis
5. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis
6. Controlled trial of prednisone and azathioprine in active chronic hepatitis
7. Current problems in the diagnosis and management of chronic active hepatitis
8. Failure of customary treatment in chronic active liver disease: causes and management
9. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen—negative chronic active hepatitis
10. Clinical features and prognosis of severe chronic liver disease (CALD) after corticosteroid‐induced remission
11. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis
12. Development and prognosis of histologic cirrhosis in corticosteroid‐treated hepatitis B surface antigen—negative chronic active hepatitis
13. Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone
14. Hepatocellular carcinoma in corticosteroid‐treated severe autoimmune chronic active hepatitis
15. Features reflective of early prognosis in corticosteroid‐treated severe autoimmune chronic active hepatitis
16. The first 100 liver transplantations at the Mayo Clinic
17. Liver transplantation
18. Clinical and prognostic implications of HLA B8 in corticosteroid‐treated severe autoimmune chronic active hepatitis
19. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and Al‐B8‐DR3 are independent risk factors
20. Influence of selected patient variables and operative blood loss on six‐month survival following liver transplantation
21. Efficacy of liver transplantation in patients with primary biliary cirrhosis
22. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting
23. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared
24. Frequency and significance of antibody to hepatitis C virus in severe corticosteroid‐treated autoimmune chronic active hepatitis
25. Analysis of HL‐A incompatibility in human renal transplants
26. HL‐A system and liver disease
27. Genetically determined immune hyperactivity in human liver disease
28. HLA A1‐B8‐DR3 and suppressor cell function in first degree relatives of patients with autoimmune chronic active hepatitis
29. Effect of corticosteroids on suppressor cell activity in autoimmune and viral chronic active hepatitis
30. Transplantation for primary biliary cirrhosis
31. “Lupoid” hepatitis, a nonentity in the spectrum of chronic active liver disease
32. Autoimmune chronic active hepatitis: a specific entity? The negative argument
33. Chronic active hepatitis: immunopathogenesis and immunotherapy
34. Mechanisms of autoimmune liver disease
35. The immunopathology of autoimmune and hepatitis B virus‐induced chronic hepatitis
36. Immune mechanisms in autoimmune chronic active hepatitis
37. Alteration in suppressor cell activity in chronic active hepatitis
38. Detection of a liver membrane autoantibody in HBsAg‐negative chronic active hepatitis
39. Chemical action and pharmacology of methotrexate, azathioprine and cyclophosphamide in man
40. Cyclosporine immunosuppression